temozolomide has been researched along with Adenoma, Prolactin-Secreting, Pituitary in 31 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas that are resistant to other therapies." | 8.95 | Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. ( Ahmad, MM; Aldabas, BS; Aljoaib, NN; Almalki, MH; Alotaibi, MJ; Alshahrani, F; Wahedi, TS, 2017) |
| "Temozolomide is an increasingly described treatment option for refractory pituitary adenomas and carcinomas." | 7.83 | Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. ( Laterra, JJ; Salvatori, R; Strowd, RE, 2016) |
| "The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) treatment." | 7.77 | A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. ( Asano, S; Ishida, Y; Katakami, H; Matsuno, A; Mizutani, A; Murakami, M; Okinaga, H; Ozawa, Y; Takano, K; Yamazaki, K, 2011) |
| "Temozolomide treatment may be an effective option for some aggressive pituitary tumors or carcinomas." | 7.76 | Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. ( Assaker, R; Bernier, M; Borson-Chazot, F; Brue, T; Caron, P; Chabre, O; Chanson, P; Cornélius, A; Cortet-Rudelli, C; de Fraipont, F; Dufour, H; Figarella-Branger, D; François, P; Gaillard, S; Jouanneau, E; Muller, M; Passagia, JG; Raverot, G; Salenave, S; Sturm, N; Trouillas, J, 2010) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 6.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "Medical treatment with the dopamine agonist, cabergoline, became the preferred first-line treatment for male prolactinomas as well as for giant tumors, leading to prolactin normalization in ~ 80% of treated men, and tumor shrinkage, improved visual fields and recovery of hypogonadism in most patients." | 5.05 | Prolactinomas in males: any differences? ( Duskin-Bitan, H; Shimon, I, 2020) |
| " Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas that are resistant to other therapies." | 4.95 | Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. ( Ahmad, MM; Aldabas, BS; Aljoaib, NN; Almalki, MH; Alotaibi, MJ; Alshahrani, F; Wahedi, TS, 2017) |
| "Temozolomide is an increasingly described treatment option for refractory pituitary adenomas and carcinomas." | 3.83 | Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. ( Laterra, JJ; Salvatori, R; Strowd, RE, 2016) |
| "The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) treatment." | 3.77 | A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. ( Asano, S; Ishida, Y; Katakami, H; Matsuno, A; Mizutani, A; Murakami, M; Okinaga, H; Ozawa, Y; Takano, K; Yamazaki, K, 2011) |
| "Temozolomide treatment may be an effective option for some aggressive pituitary tumors or carcinomas." | 3.76 | Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. ( Assaker, R; Bernier, M; Borson-Chazot, F; Brue, T; Caron, P; Chabre, O; Chanson, P; Cornélius, A; Cortet-Rudelli, C; de Fraipont, F; Dufour, H; Figarella-Branger, D; François, P; Gaillard, S; Jouanneau, E; Muller, M; Passagia, JG; Raverot, G; Salenave, S; Sturm, N; Trouillas, J, 2010) |
| "A small subset of lactotroph adenomas is resistant to dopamine agonists (DA) and can also demonstrate aggressive or even malignant behavior." | 3.01 | Refractory lactotroph adenomas. ( Karavitaki, N; Urwyler, SA, 2023) |
| "Aggressive prolactinomas are life-limiting tumors without a standard of care treatment option after the oral alkylator, temozolomide, fails to provide tumor control." | 3.01 | The treatment of aggressive prolactinomas with everolimus. ( Geer, EB; Lala, N; Lin, AL; Magge, R; Page-Wilson, G; Tabar, V; Young, RJ, 2023) |
| "Aggressive prolactinomas are defined as radiologically invasive tumors which cannot be cured by surgery, and that have an unusually rapid rate of tumor growth despite dopamine agonist treatment and surgery." | 2.66 | Aggressive prolactinomas: how to manage? ( Ilie, MD; Lasolle, H; Raverot, G, 2020) |
| "Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are challenging for their invasive nature, resistance to treatment and recurrences." | 2.66 | Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. ( Barbot, M; Bellu, L; Ceccato, F; Gardiman, MP; Lizzul, L; Lombardi, G; Losa, M; Mazza, E; Regazzo, D; Scaroni, C, 2020) |
| "Temozolomide (TMZ) has been reported to be useful as an adjunctive treatment for some patients." | 2.58 | Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission. ( Barkhoudarian, G; Eisenberg, A; Kelly, DF; Ogunbameru, R; Palejwala, SK; Wei, H, 2018) |
| "TMZ has an accepted role in treating pituitary carcinoma and adenomas if radiation and surgery have failed to control tumour growth." | 2.55 | How effective is temozolomide for treating pituitary tumours and when should it be used? ( Halevy, C; Whitelaw, BC, 2017) |
| "Fifteen of the 20 prolactinomas showed a good response to temozolomide." | 2.48 | Temozolomide in the management of dopamine agonist-resistant prolactinomas. ( Aylwin, SJ; Barazi, S; Buchanan, CR; Dworakowska, D; Gilbert, JA; Hampton, T; King, AP; Landau, DB; Lipscomb, D; Riordan-Eva, P; Thomas, NW; Whitelaw, BC, 2012) |
| "Prolactinomas are relatively unique among primary brain tumors in that medical treatment alone using dopamine agonists carries a high probability of disease control or even radiographic and endocrine remission, and thus has replaced surgery as the first line of therapy." | 2.47 | Dopamine agonist-resistant prolactinomas. ( Aghi, MK; Oh, MC, 2011) |
| "Temozolomide has recently been used for atypical adenomas or pituitary carcinomas." | 2.45 | [Recent trends in the pathophysiology and treatment of pituitary adenomas]. ( Matsuno, A, 2009) |
| " Recent reports suggested that TMZ combined with capecitabine (CAPTEM) can be effective for the treatment of aggressive pituitary tumors." | 1.72 | Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay. ( Fukuoka, H; Inoshita, N; Ishida, A; Ogawa, W; Shichi, H; Yamada, S, 2022) |
| "Prolactinomas are the most frequent pituitary tumor subtype." | 1.72 | β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models. ( Alaniz, L; Berner, S; Bonadeo, N; Cervio, A; Chimento, A; Cristina, C; Demarchi, G; Perrone, S; Sevlever, G; Spinelli, FM; Valla, S; Vitale, DL, 2022) |
| "Therapeutic agents for refractory prolactinomas that are resistant to dopamine agonists (DAs) are troublesome, and surgery often only removes a large part of the tumor without complete remission." | 1.62 | Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. ( Cheng, Y; Huang, J; Li, J; Tang, H; Wu, ZB; Zhang, B, 2021) |
| "Aggressive pituitary adenomas and pituitary carcinomas are rare and demand multiple treatment strategies." | 1.46 | Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date. ( Chen, C; Hu, Y; Jiang, S; Wang, M; Yin, S; Zhang, S; Zhou, P, 2017) |
| "Prolactinomas are a rare subset of brain tumors in pediatrics." | 1.43 | Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide. ( Felker, J; Janss, A; Patterson, B; Wrubel, D, 2016) |
| "A reduction in hormonal secretion in prolactinoma cells was also afforded by temozolomide." | 1.37 | Temozolomide-induced inhibition of pituitary adenoma cells. ( Grimsdale, R; Han, S; Nguyen, J; Rainey, J; Sheehan, J, 2011) |
| "Temozolomide (TMZ) is an alkylating cytostaticum." | 1.35 | Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. ( Andersen, M; Hagen, C; Hansen, S; Schroeder, HD, 2009) |
| "He had initially been diagnosed with prolactinoma some years before and had undergone multiple craniotomies to debulk recurrent metastatic lesions." | 1.35 | A novel use of temozolomide in a patient with malignant prolactinoma. ( Byrne, S; Karapetis, C; Vrodos, N, 2009) |
| "Prolactinomas are common tumors of the anterior pituitary gland." | 1.34 | Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. ( Cole, A; Hedges, TR; Lawrence, D; Lechan, RM; Neff, LM; Shucart, W; Tischler, AS; Weil, M; Zhu, JJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 15 (48.39) | 24.3611 |
| 2020's | 10 (32.26) | 2.80 |
| Authors | Studies |
|---|---|
| Wildemberg, LE | 1 |
| Fialho, C | 1 |
| Gadelha, MR | 1 |
| Ishida, A | 1 |
| Shichi, H | 1 |
| Fukuoka, H | 1 |
| Inoshita, N | 1 |
| Ogawa, W | 1 |
| Yamada, S | 1 |
| Borhan, MK | 1 |
| Tan, FHS | 1 |
| Demarchi, G | 1 |
| Valla, S | 1 |
| Perrone, S | 1 |
| Chimento, A | 1 |
| Bonadeo, N | 1 |
| Vitale, DL | 1 |
| Spinelli, FM | 1 |
| Cervio, A | 1 |
| Sevlever, G | 1 |
| Alaniz, L | 1 |
| Berner, S | 1 |
| Cristina, C | 1 |
| Urwyler, SA | 1 |
| Karavitaki, N | 1 |
| Lin, AL | 1 |
| Geer, EB | 1 |
| Lala, N | 1 |
| Page-Wilson, G | 1 |
| Magge, R | 1 |
| Young, RJ | 1 |
| Tabar, V | 1 |
| Lasolle, H | 2 |
| Ilie, MD | 1 |
| Raverot, G | 4 |
| Duskin-Bitan, H | 1 |
| Shimon, I | 1 |
| Lizzul, L | 1 |
| Lombardi, G | 1 |
| Barbot, M | 1 |
| Ceccato, F | 1 |
| Gardiman, MP | 1 |
| Regazzo, D | 1 |
| Bellu, L | 1 |
| Mazza, E | 1 |
| Losa, M | 1 |
| Scaroni, C | 1 |
| Tang, H | 1 |
| Cheng, Y | 1 |
| Huang, J | 1 |
| Li, J | 1 |
| Zhang, B | 1 |
| Wu, ZB | 1 |
| Cortet, C | 1 |
| Castinetti, F | 1 |
| Cloix, L | 1 |
| Caron, P | 2 |
| Delemer, B | 1 |
| Desailloud, R | 1 |
| Jublanc, C | 1 |
| Lebrun-Frenay, C | 1 |
| Sadoul, JL | 1 |
| Taillandier, L | 1 |
| Batisse-Lignier, M | 1 |
| Bonnet, F | 1 |
| Bourcigaux, N | 1 |
| Bresson, D | 1 |
| Chabre, O | 2 |
| Chanson, P | 2 |
| Garcia, C | 2 |
| Haissaguerre, M | 1 |
| Reznik, Y | 1 |
| Borot, S | 1 |
| Villa, C | 1 |
| Vasiljevic, A | 1 |
| Gaillard, S | 2 |
| Jouanneau, E | 3 |
| Assié, G | 1 |
| Almalki, MH | 1 |
| Aljoaib, NN | 1 |
| Alotaibi, MJ | 1 |
| Aldabas, BS | 1 |
| Wahedi, TS | 1 |
| Ahmad, MM | 1 |
| Alshahrani, F | 1 |
| Bilbao, I | 1 |
| Egaña, N | 1 |
| Olaizola, I | 1 |
| van der Vlist, A | 1 |
| Snijders, TJ | 1 |
| Stades, AME | 1 |
| Spliet, WGM | 1 |
| De Vos, FYFL | 1 |
| Chen, C | 1 |
| Yin, S | 1 |
| Zhang, S | 1 |
| Wang, M | 1 |
| Hu, Y | 1 |
| Zhou, P | 1 |
| Jiang, S | 1 |
| Barkhoudarian, G | 1 |
| Palejwala, SK | 1 |
| Ogunbameru, R | 1 |
| Wei, H | 1 |
| Eisenberg, A | 1 |
| Kelly, DF | 1 |
| Trouillas, J | 2 |
| Strowd, RE | 1 |
| Salvatori, R | 1 |
| Laterra, JJ | 1 |
| Halevy, C | 1 |
| Whitelaw, BC | 2 |
| Felker, J | 1 |
| Patterson, B | 1 |
| Wrubel, D | 1 |
| Janss, A | 1 |
| Hagen, C | 2 |
| Schroeder, HD | 1 |
| Hansen, S | 1 |
| Andersen, M | 1 |
| Matsuno, A | 2 |
| Byrne, S | 1 |
| Karapetis, C | 1 |
| Vrodos, N | 1 |
| Sheehan, J | 1 |
| Rainey, J | 1 |
| Nguyen, J | 1 |
| Grimsdale, R | 1 |
| Han, S | 1 |
| Sturm, N | 1 |
| de Fraipont, F | 1 |
| Muller, M | 1 |
| Salenave, S | 1 |
| Cortet-Rudelli, C | 1 |
| Assaker, R | 1 |
| Dufour, H | 1 |
| François, P | 1 |
| Passagia, JG | 1 |
| Bernier, M | 1 |
| Cornélius, A | 1 |
| Figarella-Branger, D | 1 |
| Borson-Chazot, F | 1 |
| Brue, T | 1 |
| Oh, MC | 1 |
| Aghi, MK | 1 |
| Murakami, M | 1 |
| Mizutani, A | 1 |
| Asano, S | 1 |
| Katakami, H | 1 |
| Ozawa, Y | 1 |
| Yamazaki, K | 1 |
| Ishida, Y | 1 |
| Takano, K | 1 |
| Okinaga, H | 1 |
| Dworakowska, D | 1 |
| Thomas, NW | 1 |
| Barazi, S | 1 |
| Riordan-Eva, P | 1 |
| King, AP | 1 |
| Hampton, T | 1 |
| Landau, DB | 1 |
| Lipscomb, D | 1 |
| Buchanan, CR | 1 |
| Gilbert, JA | 1 |
| Aylwin, SJ | 1 |
| Syro, LV | 2 |
| Uribe, H | 2 |
| Penagos, LC | 2 |
| Ortiz, LD | 2 |
| Fadul, CE | 2 |
| Horvath, E | 2 |
| Kovacs, K | 2 |
| Neff, LM | 1 |
| Weil, M | 1 |
| Cole, A | 1 |
| Hedges, TR | 1 |
| Shucart, W | 1 |
| Lawrence, D | 1 |
| Zhu, JJ | 1 |
| Tischler, AS | 1 |
| Lechan, RM | 1 |
13 reviews available for temozolomide and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
Prolactinomas.
Topics: Antineoplastic Agents, Alkylating; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agon | 2021 |
Refractory lactotroph adenomas.
Topics: Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma; Somatostatin; Temozolomide | 2023 |
The treatment of aggressive prolactinomas with everolimus.
Topics: Dopamine Agonists; Everolimus; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide | 2023 |
Aggressive prolactinomas: how to manage?
Topics: Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide | 2020 |
Prolactinomas in males: any differences?
Topics: Cabergoline; Dopamine Agonists; Humans; Hypogonadism; Male; Pituitary Neoplasms; Prolactinoma; Somat | 2020 |
Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Carcinoma | 2020 |
Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; Humans; Pituitary Neoplasms; Prolactinoma | 2017 |
Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Neoplasm Recurrence, Loca | 2018 |
Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Antineoplastic Agents, Alkyl | 2014 |
How effective is temozolomide for treating pituitary tumours and when should it be used?
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; O(6)-Methylguanine-DNA Methyltransferase; Pi | 2017 |
[Recent trends in the pathophysiology and treatment of pituitary adenomas].
Topics: Adenoma; Antineoplastic Agents; Cabergoline; Corticotropin-Releasing Hormone; Dacarbazine; Ergolines | 2009 |
Dopamine agonist-resistant prolactinomas.
Topics: Antineoplastic Agents, Alkylating; Cell Division; Dacarbazine; Dopamine Agonists; Drug Resistance, N | 2011 |
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
Topics: Adolescent; Adult; Dacarbazine; Dopamine Agonists; Drug Resistance, Neoplasm; Humans; Male; Prolacti | 2012 |
18 other studies available for temozolomide and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay.
Topics: Capecitabine; Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide | 2022 |
Aggressive giant prolactinoma: a case report.
Topics: Adolescent; Adult; Cabergoline; Female; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Pro | 2022 |
β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Topics: Animals; beta Catenin; Cyclin D1; Humans; Mice; Models, Theoretical; Pituitary Neoplasms; Prolactin; | 2022 |
Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.
Topics: Adult; Antineoplastic Agents, Alkylating; Dopamine Agonists; Female; Humans; Pituitary Neoplasms; Pr | 2021 |
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Chemoradiothe | 2017 |
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined | 2017 |
Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Meningeal Neoplasms; Pituitary N | 2017 |
Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Pituitary Neoplasms; Prola | 2017 |
Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; | 2016 |
Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; Female; Humans; Pituitary Neoplasms; Prognosi | 2016 |
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Female; Hormones; Humans; | 2009 |
A novel use of temozolomide in a patient with malignant prolactinoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Pituitary Neoplasms; Prol | 2009 |
Temozolomide-induced inhibition of pituitary adenoma cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Enzyme-Linked Immunosorbent A | 2011 |
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Topics: ACTH-Secreting Pituitary Adenoma; Adult; Antineoplastic Agents, Alkylating; Carcinoma; Dacarbazine; | 2010 |
A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Cell Transformation, Neoplastic; Dacarbazine; DNA Modi | 2011 |
Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.
Topics: Antineoplastic Agents; Dacarbazine; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Te | 2006 |
Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Microscopy, Electron; Middle Aged; Pit | 2007 |
Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Topics: Dacarbazine; Dopamine Agonists; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Pituitary Ne | 2007 |